Vestal Point Capital, LP Centessa Pharmaceuticals PLC Transaction History
Vestal Point Capital, LP
- $1.4 Trillion
- Q1 2025
A detailed history of Vestal Point Capital, LP transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Vestal Point Capital, LP holds 14,888 shares of CNTA stock, worth $182,526. This represents 0.02% of its overall portfolio holdings.
Number of Shares
14,888Holding current value
$182,526% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding CNTA
# of Institutions
142Shares Held
124MCall Options Held
163KPut Options Held
816K-
Medicxi Ventures Management (Jersey) LTD20MShares$245 Million75.25% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$122 Million100.0% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$119 Million4.7% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.95MShares$85.3 Million0.19% of portfolio
-
Janus Henderson Group PLC London, X05.92MShares$72.6 Million0.05% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $1.16B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...